Clinical Trials · NCT01297062
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 94
- Start date
- Feb 2011
- Locations
- 2 sites, United States
- Primary endpoint
- Comparison of Least Squares (LS) Mean Changes From Baseline in Population-based Corrected QT Intervals (QTcP) Between Exenatide and Placebo on Day 1 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 200 pg/mL)